FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients

◆ ◆ The Wire takeaway

If you're building in cardiovascular diagnostics, patient monitoring, or digital adherence tools, there's now a proven drug to anchor your clinical workflow around - and Merck has just validated that this patient population matters at scale. You have a narrow window to integrate with Lipfendra's label and clinical pathway before competitors build the same.